Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
began when the first sequence was published, and this forms the basis for …

SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being
deployed at scale, aiming to generate responses against the virus spike. The scale of the …

Virus neutralization assays measure neutralizing antibodies in serum and plasma, and the
plaque reduction neutralization test (PRNT) is considered the gold standard for measuring …

There are as yet no licensed therapeutics for the COVID-19 pandemic. The causal coronavirus
(SARS-CoV-2) binds host cells via a trimeric spike whose receptor binding domain (RBD) …

There is a vital need for authentic COVID-19 animal models to enable the pre-clinical evaluation
of candidate vaccines and therapeutics. Here we report a dose titration study of SARS-…

A novel coronavirus, SARS-CoV-2, has been identified as the causative agent of the current
COVID-19 pandemic. Animal models, and in particular non-human primates, are essential to …